Last updated: March 1, 2026
What is NDC 51660-0141?
NDC 51660-0141 corresponds to a specific pharmaceutical product approved for medical use. Based on available data, this NDC is associated with Fluticasone Propionate Nasal Spray. It is indicated for allergic rhinitis and nasal congestion relief.
Market Size and Demand
The global allergic rhinitis treatment market is valued at approximately USD 4 billion in 2023, with an expected compound annual growth rate (CAGR) of 5% over the next five years. The nasal corticosteroids sector accounts for nearly 60% of this market, totaling USD 2.4 billion.
Key factors influencing demand include:
- Increasing prevalence of allergic rhinitis globally.
- Growing awareness and diagnosis.
- Expanding access in emerging markets.
Market Segments
| Segment |
Share |
Growth Drivers |
| Prescription nasal sprays |
70% |
Physician prescribing patterns, formulary inclusion |
| Over-the-counter (OTC) options |
30% |
Consumer self-medication, regulatory changes |
Competitive Landscape
Leading products in the nasal corticosteroid segment include:
- Fluticasone Propionate (e.g., Flonase, Xhance)
- Mometasone Furoate (e.g., Nasonex)
- Budesonide (e.g., Rhinocort)
Market leaders hold significant shelf space and brand loyalty. Several competitors have biosimilar or generic versions.
Key Players
| Company |
Product Names |
Market Share (Estimated) |
| GlaxoSmithKline |
Flonase, Xhance |
45% |
| Merck & Co. |
Nasonex, Nasacort (non-fluticasone) |
20% |
| Others |
Generic/OTC brands |
35% |
Price Trends and Projections
Current Price Range
| Product Type |
Average Retail Price per Unit |
Cost for Physician Samples ($) |
Dispenser Size Configurations |
| Branded Fluticasone Spray |
USD 25–35 |
USD 0.50–1.00 |
60–120 dosage units |
| Generic Fluticasone |
USD 10–20 |
USD 0.20–0.50 |
60–120 dosage units |
Price Drivers
- Patent expiry for branded products has led to increased generic competition.
- Price erosion expected at an average rate of 10–15% annually over three years.
- Reimbursement policies in major markets influence consumer prices.
Future Price Projections (Next 3 Years)
| Year |
Estimated Price per Dose |
Factors Influencing Price |
| 2023 |
USD 0.25–0.30 |
Competitive generic entries |
| 2024 |
USD 0.20–0.25 |
Increased market penetration of generics |
| 2025 |
USD 0.15–0.20 |
Further price erosion, low-cost imports |
Regulatory and Market Entry Considerations
- Patent expirations for branded Fluticasone products occurred between 2018 and 2020.
- Multiple generics approved in the US and EU.
- Price competition is intense in mature markets, especially considering OTC options.
Key Risks and Barriers
- Regulatory delays for new formulations.
- Competition from non-fluticasone nasal sprays.
- Pressure from payers to lower prices.
- Manufacturing scale-up costs impacting margins.
Key Takeaways
- The product's market relies heavily on generic formulations, pushing prices downward.
- Competition continues to increase as patents expire.
- Future prices for NDC 51660-0141 are likely to decline by approximately 10–15% annually over the next three years.
- Market growth will be driven by expanding allergy diagnosis and treatment application.
- Entry barriers remain high for new proprietary formulations, but generics continue to capture market share.
FAQs
1. What is the primary factor driving the price decline of NDC 51660-0141?
Patent expiries and the influx of generic versions lead to increased price competition.
2. How does market growth affect the product's pricing?
Market growth increases volume sales but may not reverse declining price trends attributable to generic entry.
3. Are OTC versions of Fluticasone Propionate available?
Yes, multiple OTC versions exist, impacting prescription market prices.
4. What is the potential for new formulations or delivery systems?
Limited, as patent expirations and generic competition dominate; innovation mainly improves delivery methods rather than pricing.
5. How do reimbursement policies impact pricing?
Reimbursement pressures from insurers and government programs favor price reductions, especially in mature markets.
References
- MarketWatch. (2023). Allergic Rhinitis Treatment Market Analysis.
- IQVIA. (2023). U.S. Prescription Market Data.
- European Medicines Agency. (2022). Market Access and Approvals for Nasal Corticosteroids.
- GlobalData. (2023). Nasal Spray Market Forecasts.
- FDA. (2021). Patent Expiration Dates and Generic Approvals.
